Chapter 1. Introduction
1.1. Report description and scope
1.2. Research scope
1.3. Research methodology
1.3.1. Market research process
1.3.2. Market research methodology
Chapter 2. Executive Summary
2.1. Global osteoporosis drugs market, 2015 2021 (USD Billion)
2.2. Global osteoporosis drugs market : Snapshot
Chapter 3. Osteoporosis drugs Market Dynamics
3.1. Introduction
3.2. Market drivers
3.2.1. Global osteoporosis drugs market drivers: Impact analysis
3.2.2. Increasing the prevalence of osteoporosis
3.3. Market restraints
3.3.1. Global osteoporosis drugs market restraints: Impact analysis
3.3.2. Side effects of osteoporosis drugs
3.4. Opportunities
3.4.1. Advancement in Research and development
3.5. Porters five forces analysis
3.5.1. Bargaining power of suppliers
3.5.2. Bargaining power of buyers
3.5.3. Threat from new entrants
3.5.4. Threat from new substitutes
3.5.5. Degree of competition
3.6. Market attractiveness analysis
3.6.1. Market attractiveness analysis, by drug class segment
3.6.2. Market attractiveness analysis, by gender segment
3.6.3. Market attractiveness analysis, by regional segment
Chapter 4. Global Osteoporosis drugs Market Competitive Landscape
4.1. Company Market Share Analysis(Subject to data availability)
4.1.1. Global osteoporosis drugs market: company market share, 2015
4.2. Strategic Development
4.2.1. Acquisitions Mergers
4.2.2. New Drug class Launch
4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
4.2.4. Research and Development, Drug class and Regional Expansion
4.3. Product Portfolio
4.4. Patent Analysis (2011-2016)
4.4.1. Patent Trend
4.4.2. Patent Share by company
4.4.3. By Region
Chapter 5. Global Osteoporosis Drugs Market Drug Class Segment Analysis
5.1. Global osteoporosis drugs market: Drug class overview
5.1.1. Global osteoporosis drugs market revenue share, by drug class, 2015 and 2021
5.2. Bisphosphonates
5.2.1. Global bisphosphonates market, 2015 2021(USD Billion)
5.3. Electromagnetic Blood Flowmeters
5.3.1. Global electromagnetic blood flowmeters market , 2015 2021(USD Billion)
5.4. Rank Ligand Inhibitors
5.4.1. Global rank ligand inhibitors market , 2015 2021(USD Billion)
5.5. Parathyroid Hormone Therapy (PTH)
5.5.1. Global parathyroid hormone therapy (PTH) market , 2015 2021(USD Billion)
5.6. Selective Estrogen Receptor Modulators (SERMs)
5.6.1. Global selective estrogen receptor modulators (SERMs) market , 2015 2021(USD Billion)
Chapter 6. Global Osteoporosis Drugs Market Gender Segment Analysis
6.1. Global osteoporosis drugs market: Gender overview
6.1.1. Global osteoporosis drugs market revenue share, by gender, 2015 and 2020
6.2. Male
6.2.1. Global osteoporosis drugs market for male, 2015 2021 (USD Billion)
6.3. Female
6.3.1. Global osteoporosis drugs market for female, 2015 2021(USD Billion)
Chapter 7. Global Osteoporosis Drugs Market Regional Segment Analysis
7.1. Global osteoporosis drugs market: Regional overview
7.1.1. Global osteoporosis drugs market revenue share, by region, 2015 and 2021
7.2. North America
7.2.1. North America osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion)
7.2.2. North America osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion)
7.2.3. U.S.
7.2.3.1. U.S. osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion)
7.2.3.2. U.S. osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion)
7.3. Europe
7.3.1. Europe osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion)
7.3.2. Europe osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion)
7.3.3. Germany
7.3.3.1. Germany osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion)
7.3.3.2. Germany osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion)
7.3.4. France
7.3.4.1. France osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion)
7.3.4.2. France osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion)
7.3.5. UK
7.3.5.1. UK osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion)
7.3.5.2. UK osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion)
7.4. Asia Pacific
7.4.1. Asia Pacific osteoporosis drugs market revenue, by drug class, 2015 2021, (USD Billion)
7.4.2. Asia Pacific osteoporosis drugs market revenue, by gender, 2015 2021, (USD Billion)
7.4.3. China
7.4.3.1. China osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion)
7.4.3.2. China osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion)
7.4.4. Japan
7.4.4.1. Japan osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion)
7.4.4.2. Japan osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion)
7.4.5. India
7.4.5.1. India osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion)
7.4.5.2. India osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion)
7.5. Latin America
7.5.1. Latin America osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion)
7.5.2. Latin America osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion)
7.5.3. Brazil
7.5.3.1. Brazil osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion)
7.5.3.2. Brazil osteoporosis drugs market revenue, by gender, 2015 2021 (USD Billion)
7.6. Middle East and Africa
7.6.1. Middle East and Africa osteoporosis drugs market revenue, by drug class, 2015 2021 (USD Billion)
7.6.2. Middle East and Africa osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion)
Chapter 8. Company Profile
8.1. Novartis International AG
8.1.1. Overview
8.1.2. Financials
8.1.3. Product portfolio
8.1.4. Business strategy
8.1.5. Recent developments
8.2. Eli Lilly Amgen Inc
8.2.1. Overview
8.2.2. Financials
8.2.3. Product portfolio
8.2.4. Business strategy
8.2.5. Recent developments
8.3. Forteo
8.3.1. Overview
8.3.2. Financials
8.3.3. Product portfolio
8.3.4. Business strategy
8.3.5. Recent developments
8.4. Merck Co, Inc.
8.4.1. Overview
8.4.2. Financials
8.4.3. Product portfolio
8.4.4. Business strategy
8.4.5. Recent developments
8.5. Actavis plc
8.5.1. Overview
8.5.2. Financials
8.5.3. Product portfolio
8.5.4. Business strategy
8.5.5. Recent developments
8.6. Pfizer, Inc
8.6.1. Overview
8.6.2. Financials
8.6.3. Product portfolio
8.6.4. Business strategy
8.6.5. Recent developments
8.7. Teva Pharmaceutical Industries Ltd
8.7.1. Overview
8.7.2. Financials
8.7.3. Product portfolio
8.7.4. Business strategy
8.7.5. Recent developments
8.8. F. Hoffmann La Roche Ltd.
8.8.1. Overview
8.8.2. Financials
8.8.3. Product portfolio
8.8.4. Business strategy
8.8.5. Recent developments